Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Zalupski, MD
University of Michigan
Principal Investigator - Steven Cohen, MD
Fox Chase Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arizona Clinical Research Center
Tucson, Arizona, United States
- Us Oncology Orlando, Cancer Centers of Fl
Ocoee, Florida, United States
- Us Oncology Indiana
Indianapolis, Indiana, United States
- Univ of Michigan
Ann Arbor, Michigan, United States
- Us Oncology Albany, New York Oncology
Albany, New York, United States
- Us Oncology Kettering
Kettering, Ohio, United States
- Fox Chase Cancer Ctr.
Philadelphia, Pennsylvania, United States
- Us Oncology, Virginia Oncology Assoc
Norfolk, Virginia, United States
- Us Oncology Northwest, Northwest Cancer Specialists
Vancouver, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Feb 2004
- Primary completion
- 31 Oct 2009
- Completion
- 31 Oct 2009
- Last update posted
- 15 Sept 2010
- Registered enrollment
- 105
- Registry id
- NCT00327327
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.